SLNSW-Blood serum amyloid A as potential biomarker of p...-TN_cdi_proquest_journals_2530262874

Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study

Full title: Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study

Author/creator: Di Noia, Vincenzo, D’Argento, Ettore, Pilotto, Sara, Vita, Emanuele, Ferrara, Miriam Grazia, Damiano, Paola, Ribelli, Marta, Cannella, Antonella, Virtuoso, Antonella, Fattorossi, Andrea, Ceresoli, Giovanni Luca, Milella, Michele, Beretta, Giordano Domenico, Tortora, Giampaolo, Bria, Emilio.

Call Numbers:

Record Identifier: TN_cdi_proquest_journals_2530262874

Language: English

Formats: Articles

Publishers: Berlin/Heidelberg: Springer Berlin Heidelberg

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2530262874

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study

    Record identifier

    TN_cdi_proquest_journals_2530262874

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2530262874

    Share

    Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2530262874

    Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study

    Full title

    Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study

    Author / Creator

    Di Noia, Vincenzo ; D’Argento, Ettore ; Pilotto, Sara ; Vita, Emanuele ; Ferrara, Miriam Grazia ; Damiano, Paola ; Ribelli, Marta ; Cannella, Antonella ; Virtuoso, Antonella ; Fattorossi, Andrea ; Ceresoli, Giovanni Luca ; Milella, Michele ; Beretta, Giordano Domenico ; Tortora, Giampaolo ; Bria, Emilio

    Publisher

    Berlin/Heidelberg: Springer Berlin Heidelberg

    Journal title

    Cancer Immunology, Immunotherapy, 2021, Vol.70 (6), p.1583-1592

    Record Identifier

    TN_cdi_proquest_journals_2530262874

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Adenocarcinoma of Lung - blood Adenocarcinoma of Lung - drug therapy Adenocarcinoma of Lung - pathology Adult Aged Aged, 80 and over Analysis Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents, Immunological B7-H1 Antigen - metabolism Biomarker of response Biomarkers Biomarkers, Tumor - blood Blood Cancer Research Carcinoma, Non-Small-Cell Lung - blood Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Carcinoma, Squamous Cell - blood Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - pathology Case-Control Studies Chemotherapy Female Follow-Up Studies Humans Immune checkpoint Immune response Immunology Immunotherapy Lung cancer Lung cancer, Non-small cell Lung Neoplasms - blood Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male Medicine Medicine & Public Health Metastases Middle Aged Monoclonal antibodies Multivariate analysis Non-small cell lung carcinoma NSCLC Oncology Original Original Article PD-L1 protein Pembrolizumab Pleural effusion Predictive Prognosis prognostic factors to immune-checkpoint inhibitors Prospective Studies Serum amyloid A Serum Amyloid A Protein - analysis Small cell lung carcinoma Survival Rate Targeted cancer therapy

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_proquest_journals_2530262874

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2530262874

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections